Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -5.02% and Operating profit at 43.89% over the last 5 years
2
Negative results in Mar 26
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,645 Million (Mid Cap)
26.00
NA
2.89%
-0.44
9.42%
2.43
Revenue and Profits:
Net Sales:
400 Million
(Quarterly Results - Jun 2026)
Net Profit:
58 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.32%
0%
13.32%
6 Months
-9.41%
0%
-9.41%
1 Year
-31.63%
0%
-31.63%
2 Years
33.4%
0%
33.4%
3 Years
28.18%
0%
28.18%
4 Years
20.18%
0%
20.18%
5 Years
43.96%
0%
43.96%
Changzhou Qianhong Biopharma Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.02%
EBIT Growth (5y)
43.89%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.59
Tax Ratio
17.77%
Dividend Payout Ratio
46.07%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.61%
ROE (avg)
8.97%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
2.68
EV to EBIT
18.17
EV to EBITDA
15.76
EV to Capital Employed
4.05
EV to Sales
4.31
PEG Ratio
NA
Dividend Yield
2.51%
ROCE (Latest)
22.30%
ROE (Latest)
10.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
400.30
410.90
-2.58%
Operating Profit (PBDIT) excl Other Income
78.10
113.50
-31.19%
Interest
0.00
0.00
Exceptional Items
4.20
1.20
250.00%
Consolidate Net Profit
58.40
92.00
-36.52%
Operating Profit Margin (Excl OI)
149.20%
236.40%
-8.72%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -2.58% vs 4.16% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -36.52% vs 22.50% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,557.10
1,510.10
3.11%
Operating Profit (PBDIT) excl Other Income
497.80
429.30
15.96%
Interest
0.70
1.50
-53.33%
Exceptional Items
6.50
3.50
85.71%
Consolidate Net Profit
373.30
333.20
12.03%
Operating Profit Margin (Excl OI)
274.90%
238.00%
3.69%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.11% vs -16.18% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 12.03% vs 86.46% in Dec 2024
About Changzhou Qianhong Biopharma Co., Ltd. 
Changzhou Qianhong Biopharma Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






